国际肿瘤学杂志

国际肿瘤学杂志 ›› 2013, Vol. 40 ›› Issue (6): 431-433.

• 综述 • 上一篇    下一篇

趋化因子受体CXCR7及其与肿瘤的关系

王娜娜, 支宇, 白鹰   

  1. 116021 大连大学附属新华医院神经科 (王娜娜、白鹰)，肛肠科 （支宇）
  • 出版日期:2013-06-08 发布日期:2013-05-24
  • 通讯作者: 白鹰，E-mail：yingbai@yahoo.cn E-mail:yingbai@yahoo.cn

Chemokine receptor CXCR7 and tumor

WANG  Na-Na, ZHI  Yu, BAI  Ying   

  1. Department of Neurology, Affiliated Xinhua Hospital, Dalian University, Dalian 116021, China
  • Online:2013-06-08 Published:2013-05-24
  • Contact: BAI Ying E-mail:yingbai@yahoo.cn

PDF

1547

被引次数

1

摘要： CXCR7是继CXCR4之后发现的趋化因子CXCL12的新受体。目前研究表明，CXCL12/CXCR7生物轴对多种肿瘤的发展有重要影响，与CXCL12/CXCR4生物轴的作用有一定相似性。CXCR7广泛表达于多种肿瘤组织及肿瘤细胞，在肿瘤细胞的生长增殖、黏附迁徙中起重要作用。抑制CXCR7表达或阻断其信号传导通路可能为肿瘤治疗提供新策略。

关键词: 肿瘤, 趋化因子CXCL12, CXCR7

Abstract: CXCR7 is a new receptor of chemokine CXCL12 after CXCR4. The present study shows that CXCL12/CXCR7 biological axis has important influence to the  development of a variety of tumors, similar to CXCL12/CXCR4 biological axis. CXCR7 is present in many kinds of tumor tissues and tumor cells widely, and plays an important role in tumor cells growth, proliferation, adhesion and migration. Restraining CXCR7 expression or blocking the CXCR7 signaling pathways may offer new strategies for the treatment of tumors.

Key words: Immunosuppression, Inflammation, Neoplasms, T-lymphocytes, regulatory, Myeloid-derived suppressor cells